Showing 681-690 of 3737 results for "".
Long Shot: Daxxify Shows Promise
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/long-shot-daxxify-shows-promise/23819/Charles Boyd, MD and Marina Peredo, MD highlight the Daxxify difference.Physician Spotlight: Brian Adams, MD, MPH
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-brian-adams-md-mph/23534/Physician Spotlight: George Han, MD, PhD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-george-han-md-phd/23666/Physician Spotlight: Anna L. Chien, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-anna-l-chien-md/23488/Physician Spotlight: Jeffrey S. Dover, MD, FRCPC
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-jeffrey-s-dover-md-frcpc/23854/Physician Spotlight: Christopher Bunick, MD, PhD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-christopher-bunick-md-phd/23911/Intergenerational Dermatology: Three Generations of Dermatologists Reflect on the Field
https://practicaldermatology.com/topics/general-topics/intergenerational-dermatology-three-generations-of-dermatologists-reflect-on-the-field/23992/With Sorrel S. Resnik, MD, Barry Resnik, MD, and Sydney Resnik, MD, by Heidi SpleteConsiderations for Treatment Downtime After Laser Therapy in Scar Repair
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/considerations-for-treatment-downtime-after-laser-therapy-in-scar-repair-/18625/E. Victor Ross, MD discusses how treatment downtime influences his approach for treating scars. His goal, he said, is to achieve the highest degree of efficacy possible with laser used as mono- or combination therapy while being mindful of patients' comfort levels with the associated recovery periodEmerging Vitiligo Therapies
https://practicaldermatology.com/conferences/maui-derm-2022/emerging-vitiligo-therapies/20047/It’s really an exciting time to be treating vitiligo, says John E. Harris, MD, PhD. He reviews Phase 2 and 3 clinical trials for ruxolitinib, a topical JAK inhibitor, and the hope that the FDA could soon approve it for the treatment of vitiligo. He also discusses other possible targeted treatments iSkin of Color Session: Dr. Harris
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/skin-of-color-session-dr-harris/32683/John E. Harris, MD, PhD, summarizes his vitiligo talk from the "Skin of Color Session" at Maui Derm 2025, during which he covered new therapeutic options for vitiligo as well as promising drugs in the pipeline and why they could be so impactful.